Mainly, CD38 is co-expressed with PD-1 and CTLA-4 on tumor-infiltrating CD8+ TRM cells, identifying CD38 as a potential immune checkpoint marker that could be harnessed for HCC immunotherapy. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.